Second Sight Medical Products Inc (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that provide some useful vision to blind patients, announced the appointment of Will McGuire, a 20-year veteran of the life sciences industry, as President and Chief Executive Officer (CEO) of Second Sight, effective August 18, 2015.Mr. McGuire succeeds Dr. Robert Greenberg, who will become Chairman of the Board of Directors of Second Sight, replacing Alfred Mann, who will assume the role of Chairman Emeritus.
“Will brings an immense depth of experience in the life sciences industry that will advance Second Sight’s commercialization of the Argus® II Retinal Prosthesis. After a thorough search process, management and the Board of Directors are confident that Will’s broad experience, execution expertise, and strong leadership skills make him the right individual to fully commercialize and rapidly expand our business,” said Dr. Greenberg, current President and CEO of Second Sight.
“I look forward to working closely with Will and the Board of Directors in my role as Chairman, with the shared goal of advancing next generation products such as the Orion® I Visual Cortical Prosthesis and other initiatives to further build value for patients and shareholders alike. In this effort we will also benefit from the ongoing contributions of Al Mann, who will continue to provide valuable counsel to Second Sight as Chairman Emeritus,” added Dr. Greenberg.
“We are excited to welcome Will to Second Sight. His addition strengthens an already outstanding management team that has brought vision within the reach of so many blind individuals. Furthermore, I believe Bob will continue to inspire, in his role as Chairman, with as much skill as he led the Company as President and CEO. I am confident all of our constituents will be well served in their capable hands,” added Alfred Mann, current Chairman of the Board of Second Sight.
Will McGuire joins Second Sight from Volcano Corporation, where he was President of Americas Commercial since 2014 and Senior Vice President and General Manager of Coronary Imaging, Systems and Program Management since 2013. Volcano, the global leader in intravascular imaging for coronary and peripheral applications and physiology, was acquired by Royal Philips in February 2015. Prior to joining Volcano, Mr. McGuireserved as Vice President and General Manager of Patient Monitoring at Covidien. He previously served as President and Chief Executive Officer of AtheroMed, Inc., a venture capital-backed peripheral atherectomy company, prior to which he was Chief Operating Officer at Spectranetics Corporation, a publicly-traded medical device company. In addition, Mr. McGuire held various positions at Guidant Corporation from 1998 to 2005 including General Manager of Guidant Latin America; Director of U.S. Marketing for Vascular Intervention (VI); Director of Global Marketing for VI; and, Production Manager for Coronary Stents. Prior to 1998, Mr. McGuire held positions in Finance and Production at IVAC Medical Systems. A graduate of the Georgia Institute of Technology, Mr. McGuire received his M.B.A. from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill. (Original Source)
Shares of Second Sight Medical Products closed yesterday at $15.73 . EYES has a 1-year high of $24.02 and a 1-year low of $8.05. The stock’s 50-day moving average is $13.56 and its 200-day moving average is $12.45.
Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa.